Modality
Cell Therapy
MOA
FXIai
Target
GPRC5D
Pathway
Notch
Ovarian CaSCLCParkinson's
Development Pipeline
Preclinical
Dec 2018
→ Dec 2025
PreclinicalCurrent
NCT08435468
764 pts·SCLC
2019-05→TBD·Active
NCT08040161
1,820 pts·Ovarian Ca
2018-12→2025-12·Terminated
2,584 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-12-223mo agoInterim· Ovarian Ca
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
Preclinical
Termina…
Preclinical
Active
Catalysts
Interim
2025-12-22 · 3mo ago
Ovarian Ca
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08435468 | Preclinical | SCLC | Active | 764 | NT-proBNP |
| NCT08040161 | Preclinical | Ovarian Ca | Terminated | 1820 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| Semazasiran | BeiGene | Phase 1 | PD-1 |